Increased risk of severe cutaneous adverse reactions when cladribine is used together with other medications with a propensity for skin reactions

References

• Robak T, Matutes E, Catovsky D, et al. Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v100–7.
   PubMedGoogle Scholar
• Wierda WG, Byrd JC, Abramson JS, et al. Hairy cell leukemia, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(11):1414–1427.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23–33.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760. Jun 21
   PubMed Web of Science ®Google Scholar
• Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol. 1998;16(9):3007–3015.
   PubMed Web of Science ®Google Scholar
• SmPC: Cladribine 2021; [updated 23 December 2021; cited 2021 1 April 2022]. Available from: https://www.medicines.org.uk/emc/product/13187/smpc.
   Google Scholar
• Castagna J, Amsler E, Kurihara F, et al. Atypical features of cutaneous adverse drug reactions during therapy for hairy cell leukemia. J Allergy Clin Immunol Pract. 2020;8(9):3203–3206 e1.
   PubMed Web of Science ®Google Scholar
• Meher-Homji Z, Tam CS, Siderov J, et al. High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia – lessons for immunopathogenesis and prescribing. Leuk Lymphoma. 2019;60(14):3455–3460.
   PubMed Web of Science ®Google Scholar
• Robak E, Jesionek-Kupnicka D, Robak T. Skin changes in hairy cell leukemia. Ann Hematol. 2021;100(3):615–625.
   PubMed Web of Science ®Google Scholar
• Seymour J, Kurzrock R, Freireich E, et al. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood. 1994;83(10):2906–2911.
   PubMed Web of Science ®Google Scholar
• Bastie JN, Cazals-Hatem D, Daniel MT, et al. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment. Leuk Lymphoma. 1999;35(5–6):555–565.
   PubMed Web of Science ®Google Scholar
• Raspadori D, Rondelli D, Birtolo S, et al. Long-lasting decrease of CD4+/CD45RA + T cells in HCL patients after 2-chlorodeoxyadenosine (2-CdA) treatment. Leukemia. 1999;13(8):1254–1257.
   PubMed Web of Science ®Google Scholar
• Correia O, Delgado L, Ramos JP, et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis: further evidence of CD8+ lymphocyte involvement. Arch Dermatol. 1993;129(4):466–468.
   PubMedGoogle Scholar
• Roujeau JC, Moritz S, Guillaume JC, et al. Lymphopenia and abnormal balance of T-lymphocyte subpopulations in toxic epidermal necrolysis. Arch Dermatol Res. 1985;277(1):24–27.
   PubMed Web of Science ®Google Scholar
• Weinkle A, Pettit C, Jani A, et al. Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation-A retrospective chart review. J Am Acad Dermatol. 2019;81(3):749–757.
   PubMed Web of Science ®Google Scholar
• Ganzel C, Gatt ME, Maly A, et al. High incidence of skin rash in patients with hairy cell leukemia treated with cladribine. Leuk Lymphoma. 2012;53(6):1169–1173.
   PubMed Web of Science ®Google Scholar
• Johnston JB, Glazer RI, Pugh L, et al. The treatment of hairy-cell leukaemia with 2′-deoxycoformycin. Br J Haematol. 1986;63(3):525–534.
   PubMed Web of Science ®Google Scholar
• O’Dwyer P, King S, Eisenhauer E, et al. Hypersensitivity reactions to deoxycoformycin. Cancer Chemother Pharmacol. 1989;23(3):173–175.
   PubMed Web of Science ®Google Scholar
• Wang RF, Li D, Kuehn GJ, et al. Antibiotic exposure is associated with cutaneous adverse events in hairy cell leukemia patients treated with purine analogues. J Am Acad Dermatol. 2019;80(6):1762–1764.
   PubMed Web of Science ®Google Scholar
• Martin P, Barr PM, James L, et al. Long-term safety experience with bendamustine for injection in a real-world setting. Expert Opin Drug Saf. 2017;16(6):647–650.
   PubMed Web of Science ®Google Scholar
• Brown GL, Kanwar BS. Drug rashes in glandular fever. Lancet. 1967;2(7531):1418.
   PubMed Web of Science ®Google Scholar
• Patel BM. Skin rash with infectious mononucleosis and ampicillin. Pediatrics. 1967;40(5):910–911.
   PubMed Web of Science ®Google Scholar
• Pullen H, Wright N, Murdoch JM. Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis. Lancet. 1967;290(7527):1176–1178.
   Google Scholar
• Coopman SA, Johnson RA, Platt R, et al. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993;328(23):1670–1674.
   PubMed Web of Science ®Google Scholar
• Jenson HB. Epstein-Barr virus. Pediatr Rev. 2011;32(9):375–383; quiz 384.
   PubMed Web of Science ®Google Scholar
• Thompson DF, Ramos CL. Antibiotic-induced rash in patients with infectious mononucleosis. Ann Pharmacother. 2017;51(2):154–162.
   PubMed Web of Science ®Google Scholar
• Chubar Y, Bennett M. Cutaneous reactions in hairy cell leukaemia treated with 2-chlorodeoxyadenosine and allopurinol. Br J Haematol. 2003;122(5):768–770.
   PubMed Web of Science ®Google Scholar
• Meunier P, Castaigne S, Bastie JN, et al. Cutaneous reactions after treatment with 2-chlorodeoxyadenosine. Acta Derm Venereol. 1996;76(5):385–386.
   PubMed Web of Science ®Google Scholar
• Ingen-Housz-Oro S, Bernier C, Gener G, et al. Valaciclovir: a culprit drug for drug reaction with eosinophilia and systemic symptoms not to be neglected. Three cases. Br J Dermatol. 2019;180(3):666–667.
   PubMed Web of Science ®Google Scholar
• Hazell L, Shakir SAW. Under-reporting of adverse drug reactions. Drug Saf. 2006;29(5):385–396.
   PubMed Web of Science ®Google Scholar